Dishman Carbogen Amcis Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Trading below book value (P/B 0.5x)
- Low debt relative to equity (D/E 0.5x)
- Near 52-week low — potential value zone (₹128)
Concerns
- Low capital efficiency (ROCE 3.1%)
- Premium to sector peers (P/E 118x vs industry 50.2x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
DCAL · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
| FII | 8.60% | 8.70% | 8.05% | 8.18% | 8.75% | 9.49% |
| DII | 3.68% | 2.36% | 1.47% | 1.22% | 1.42% | 1.26% |
| Public | 28.39% | 29.63% | 31.17% | 31.29% | 30.51% | 29.94% |
Latest News
All newsDishman Carbogen Amcis announces board meeting outcomes
*Dishman Carbogen Amcis announces board meeting outcomes.* The company disclosed outcomes from its recent board meeting held on October 7, 2026. Key deliberations included **routine corporate matters** with no major financial announcements. Investors await further disclosures for strategic updates. 📊 *STOCKS:* $DCAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Dishman Carbogen Amcis announces board meeting outcome
*Dishman Carbogen Amcis announces board meeting outcome.* The company disclosed the outcome of its August 12, 2026, board meeting, detailing routine corporate matters. No significant financial decisions or strategic announcements were revealed. The filing is primarily procedural in nature. 📊 *STOCKS:* DCAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #BoardMeeting
Dishman Carbogen Amcis to hold shareholder meeting on September 30, 2026
*Dishman Carbogen Amcis to hold shareholder meeting on September 30, 2026.* The event is a routine corporate disclosure with no immediate financial implications. No major agenda items disclosed yet. Such meetings typically address statutory or governance matters. 📊 *STOCKS:* $DCAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]
HealthcarePharmaceuticals & Biotechnology